($1 = 0.8524 euros) (Reporting by Paul Arnold and Oliver Hirt Writing by Christoph Steitz Editing by Michelle Martin)ZURICH — Switzerland-based PSquared Asset Management on Wednesday unveiled a stake of more than 4% in Qiagen, adding it would not tender its shares into a $12.9 billion offer by U.S. laboratory equipment supplier Thermo Fisher.The next issue of Top Stories Newsletter will soon be in your inbox.There was an error, please provide a valid email address.Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.A welcome email is on its way. - Offer price increased from €39.00 to €43.00 per QIAGEN share in cash - Minimum acceptance threshold lowered from 75% to 66.67% of outstanding QIAGEN shares - QIAGEN Supervisory and Managing Boards reaffirm unanimous recommendation that QIAGEN shareholders tender all of their QIAGEN shares Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN … The terms and conditions of the tender offer are published in, and the offer to purchase ordinary shares of QIAGEN is made only pursuant to, the offer document, the publication of which was permitted by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), and related offer … The terms and conditions of the tender offer are published in, and the offer to purchase ordinary shares of QIAGEN is made only pursuant to, the offer document as permitted for publication …
“PSquared will not tender any shares into the current offer.”“PSquared believes that the current cash offer by Thermo Fisher at 43 euros ($50.45) per share materially undervalues Qiagen on a standalone basis,” the fund said in response to a Reuters request.Hedge fund Davidson Kempner, which says it owns more than 5% of Qiagen, a day earlier said it would not tender its shares into the offer, adding a price of between 48 euros and 52 euros a share was more appropriate.Reporting by Paul Arnold and Oliver Hirt; Writing by Christoph Steitz; Editing by Michelle Martin The terms and conditions of the tender offer will be published in, and the offer to purchase ordinary shares of QIAGEN will be made only pursuant to, the offer document and related offer … If you don't see it please check your junk folder.We encountered an issue signing you up. Switzerland-based PSquared Asset Management on Wednesday unveiled a stake of more than 4% in Qiagen , adding it would not tender its shares into a $12.9 billion offer by U.S. laboratory …
Please try again365 Bloor Street East, Toronto, Ontario, M4W 3L4 Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of QIAGEN. The amendment provides for an increase from the original offer price of €39.00 to a new price of €43.00 per QIAGEN share in cash, which represents a premium of approximately 35% to the closing price of QIAGEN’s ordinary shares on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the acquisition agreement and Thermo Fisher’s intention to … The offer price represents a premium of approximately 23% to the closing price of QIAGEN’s common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. The Tender Offer is subject to certain customary closing conditions, including, among others, the receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at QIAGEN's general meeting of shareholders (the "General Meeting"), and a minimum acceptance threshold of at least 75% of QIAGEN's issued and outstanding ordinary share capital as of the end of the … The fund which holds 3.1% of Qiagen shares, said the company should be sold for 50 euros ($57.21) a share, far below Thermo Fisher’s current offer of 39 euros. (RTTNews) - Thermo Fisher Scientific Inc. (TMO) published the offer document for its voluntary tender offer for all of the ordinary shares of QIAGEN N.V. (QGEN) at an offer price of 39 … The terms and conditions of the tender offer are published in, and the offer to purchase ordinary shares of QIAGEN is made only pursuant to, the offer document, the publication of which was permitted by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), and related offer … Unauthorized distribution, transmission or republication strictly prohibited.“PSquared will not tender any shares into the current offer.”Hedge fund Davidson Kempner, which says it owns more than 5% of Qiagen, a day earlier said it would not tender its shares into the offer, adding a price of between 48 euros and 52 euros a share was more appropriate.